52 related articles for article (PubMed ID: 36746687)
1. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
Cheng WC; Chen HF; Cheng HC; Li CY
Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
[TBL] [Abstract][Full Text] [Related]
2. Influence of MAFLD and NAFLD on arterial stiffness: A longitudinal cohort study.
Yoo TK; Lee SW; Lee MY; Choi H; Sung KC
Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1769-1778. PubMed ID: 38644081
[TBL] [Abstract][Full Text] [Related]
3. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
[TBL] [Abstract][Full Text] [Related]
4. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
Song R; Li Z; Zhang Y; Tan J; Chen Z
Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
[TBL] [Abstract][Full Text] [Related]
5. Metabolic dysfunction-associated fatty liver disease increases the risk of type 2 diabetes mellitus in young Korean adults.
Ha J; Hong OK; Han K; Kwon HS
Diabetes Res Clin Pract; 2024 Jun; 212():111584. PubMed ID: 38367650
[TBL] [Abstract][Full Text] [Related]
6. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.
Mayén AL; Sabra M; Aglago EK; Perlemuter G; Voican C; Ramos I; Debras C; Blanco J; Viallon V; Ferrari P; Olsen A; Tjønneland A; Langmann F; Dahm CC; Rothwell J; Laouali N; Marques C; Schulze MB; Katzke V; Kaaks R; Palli D; Macciotta A; Panico S; Tumino R; Agnoli C; Farràs M; Molina-Montes E; Amiano P; Chirlaque MD; Castilla J; Werner M; Bodén S; Heath AK; Tsilidis K; Aune D; Weiderpass E; Freisling H; Gunter MJ; Jenab M
BMC Med; 2024 Jun; 22(1):221. PubMed ID: 38825687
[TBL] [Abstract][Full Text] [Related]
7. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals.
Zhang P; Zeng Y; Yang S; Ye C; Wang M; Peng T; Li L; Dong X
Sci Rep; 2024 May; 14(1):11320. PubMed ID: 38760435
[TBL] [Abstract][Full Text] [Related]
8. Sex and Age Differences in the Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Heart Failure: A Prospective Cohort Study.
Wu S; Li Y; Zhang Y; Su X; Zuo Y; Chen G; Xu G; Chen S; He Y; Wang A
Circ Heart Fail; 2024 Feb; 17(2):e010841. PubMed ID: 38348678
[TBL] [Abstract][Full Text] [Related]
9. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver.
Park H; Yoon EL; Kim M; Kim JH; Cho S; Jun DW; Nah EH
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640643
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease.
Badmus OO; Hinds TD; Stec DE
Curr Hypertens Rep; 2023 Aug; 25(8):151-162. PubMed ID: 37191842
[TBL] [Abstract][Full Text] [Related]
11. A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLD.
Li Z; Gong R; Chu H; Zeng J; Chen C; Xu S; Hu L; Gao W; Zhang L; Yuan H; Cheng Z; Wang C; Du M; Zhu Q; Zhang L; Rong L; Hu X; Yang L
Atherosclerosis; 2024 May; 392():117526. PubMed ID: 38581738
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated fatty liver disease in the elderly with diabetic foot ulcers: A longitudinal cohort study.
Zhang L; Lin Y; Huang X; Zhai Z; Wei R; Mo J; Li J; Lu W
Int Wound J; 2024 Apr; 21(4):e14586. PubMed ID: 38102851
[TBL] [Abstract][Full Text] [Related]
13. Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome.
Hsu CL; Lang S; Demir M; Fouts DE; Stärkel P; Schnabl B
Hepatology; 2023 Jun; 77(6):2073-2083. PubMed ID: 36631002
[TBL] [Abstract][Full Text] [Related]
14. INASL-SAASL Consensus Statements on NAFLD Name Change to MAFLD.
Singh SP; Duseja A; Mahtab MA; Anirvan P; Acharya SK; Akbar SMF; Butt AS; Dassanayake A; De A; Dhakal GP; Hamid S; Madan K; Panigrahi MK; Rao PN; Saigal S; Satapathy SK; Shalimar ; Shrestha A; Shukla A; Sudhamshu KC; Wijewantha H
J Clin Exp Hepatol; 2023; 13(3):518-522. PubMed ID: 37250868
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: results from a single-center biopsy study.
Kaya E; Yilmaz Y
Chin Med J (Engl); 2024 Mar; 137(5):616-618. PubMed ID: 38317478
[No Abstract] [Full Text] [Related]
16. The Independent Association of Non-alcoholic Fatty Liver Disease With Incident Cardiovascular Disease: A GRADE Evaluation of the Evidence Through a Systematic Review and Meta-analysis.
Prasad M; Gupta S; Sarin SK
J Clin Exp Hepatol; 2024; 14(1):101277. PubMed ID: 38076375
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis.
Virk GS; Vajje J; Virk NK; Mannam R; Rehman W; Ghobriel NG; Mian IU; Usama M
Cureus; 2023 Aug; 15(8):e44413. PubMed ID: 37791219
[TBL] [Abstract][Full Text] [Related]
18. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes.
Vaz K; Clayton-Chubb D; Majeed A; Lubel J; Simmons D; Kemp W; Roberts SK
Hepatol Int; 2023 Oct; 17(5):1082-1097. PubMed ID: 37556065
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cardiovascular mortality between MAFLD and NAFLD: A cohort study.
Yoo TK; Lee MY; Kim SH; Zheng MH; Targher G; Byrne CD; Sung KC
Nutr Metab Cardiovasc Dis; 2023 May; 33(5):947-955. PubMed ID: 36746687
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
